Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

190 results about "Drug content" patented technology

Automatic detection method for noon tea product

The invention relates to the technical field of automatic detection of noon tea products, in particular to an automatic detection method of noon tea products, which comprises the following steps: sampling and equally dividing clathrated finished products in a storage area as detection samples, comprehensively evaluating the drug content state, apparent state and clathration degree state of the detection samples, and determining the content of the noon tea products. And continuously executing the process to obtain the inclusion effect evaluation value of a group of detection samples, further analyzing the inclusion standard-reaching rate of the group of detection samples, predicting the inclusion standard-reaching state of residual finished products based on the inclusion standard-reaching rate, and outputting a qualified or unqualified signal in real time. Therefore, rapid and accurate detection of the noon tea inclusion effect is realized, the detection efficiency and the quality control level are remarkably improved, and powerful power is injected for enterprise production optimization and market competition.
Owner:JINHUA FOOD & DRUG INSPECTION & TESTING RES INST

Imaging-based pharmaceutical content verification in a robotic preparation system

Label image information is used to automatically identify and / or verify the identification of pharmaceutical substances, in conjunction with the automatic preparation of pharmaceutical preparations from those pharmaceutical substances. In some examples, textual content of substance containers is identified using OCR. This corresponds to a significant portion of the label information intended for human inspection. As a cross-check, one or more additional visual aspects of the label are evaluated, e.g., an aspect of graphical appearance other than textual content as such. Optionally, risks of mis-identification are evaluated. Optionally, imperfect matches to templates are deemed permissible due to a low risk of actual misidentification, and / or close but potentially ambiguous template matches are deemed insufficiently risk free, resulting in mitigation actions.
Owner:EQUASHIELD MEDICAL

Mabazavir oral soluble film agent and preparation method thereof

The invention discloses a macloxvir oral soluble film agent and a preparation method thereof, and relates to the technical field of medicines. The macloxvir oral soluble film agent comprises the following components in percentage by weight: 10%-20% of macloxvir, 10%-70% of a film-forming material, 3%-15% of a disintegrating agent, 2%-25% of a plasticizer, 0%-5% of a flavoring agent and 0%-3% of an auxiliary material. The macloxvir oral soluble film preparation has the advantages of no irritant taste, smooth surface, uniform drug content, fast disintegration speed, fast absorption, convenient administration, and improvement of the compliance of patients. The film agent can be used for resisting viruses.
Owner:HARBIN PHARMA GROUP TECH CENT

Microneedle patch system for transdermal drug delivery

The present invention relates to a microneedle patch system for continuously administering a large amount of drug to the skin. A microneedle patch provided by one aspect of the present invention may have increased drug content per unit area (1 cm2) to maximum of 100 mg unlike existing microneedles and thus has a higher drug content per unit area than an existing transdermal absorption agent, and is capable of delivering the drug into the body for a short time (within 24 hours) and a long time (approximately three days or more) via micropores formed by means of microneedles.
Owner:INDUSTRYACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY

Film agent of lumepirone or salt thereof and preparation method of film agent

ActiveCN119970685AOrganic active ingredientsNervous disorderDrug contentOral mucous membrane
The invention provides a film agent of lumepirone or salt thereof and a preparation method of the film agent, and relates to the technical field of medicines. The lumepirone injection comprises the following raw materials in parts by mass: 2-30 parts of lumepirone or pharmaceutically acceptable salt thereof, 40-95 parts of a film-forming material, 1-30 parts of a plasticizer and 0.1-5 parts of an antioxidant, the antioxidant is selected from at least one of butylated hydroxyanisole, butylated hydroxytoluene and sodium hydrogen sulfite. The film agent is used for drug delivery through oral mucosa or a sublingual way, so that the bioavailability of the drug can be remarkably improved, the blood concentration can be increased, the drug content in the brain and the D2 target spot occupancy rate can be increased, and the curative effect of the film agent can be effectively enhanced.
Owner:HANGZHOU CHENGBANG PHARMACEUTICAL TECHNOLOGY CO LTD

Ketotifen fumarate divided dose tablet based on 3D printing technology and preparation method

The invention discloses a ketotifen fumarate divided-dose tablet based on a 3D printing technology and a preparation method thereof. The ketotifen fumarate clinical divided-dose tablet comprises the following components in percentage by mass: 1-10% of ketotifen fumarate tablet powder, 90-99% of cocoa butter and 0-5% of a flavoring agent, and the sum of the mass percentages of the components is equal to 100%. According to the technical scheme, a hot-melt extrusion type 3D printing technology is adopted to achieve rapid dissolution and clinical precise dose division of tablets, the 3D printing technology is applied to the field of dose division of commercially available tablets, and tablet powder and heated and melted pharmaceutic adjuvants are evenly mixed to prepare a printing material; the dose of the 3D printing divided dose tablet is accurately controlled by adjusting the drug content of the printing material and the volume of the printing model; the content of medicines in commercially available tablets is diluted by adding pharmaceutic adjuvants, and small-dose tablets with lower content are prepared again, so that precise dose-divided administration is realized, and the purpose of individualized administration is achieved.
Owner:SHENZHEN CITY BAOAN DISTRICT MATERNAL & CHILD HEALTH HOSPITAL

Method and system for trace analysis of antiviral drugs in sewage based on LC-MS / MS

The invention relates to the field of drug analysis, and discloses a trace analysis method and system for antiviral drugs in sewage based on LC-MS / MS. The method comprises the following steps: filtering a sewage sample, analyzing the drug properties of the antiviral drugs, carrying out solid-phase extraction on the filtered sewage sample, preparing an LC-MS / MS module of the extracted sample, determining a mobile phase of a chromatographic column, and determining the mobile phase of the chromatographic column. Balancing the chromatographic column, constructing chromatographic conditions for balancing the chromatographic column, determining a tuning solution and a mass axis calibration compound of a mass spectrometer, calibrating the mass spectrometer, and constructing mass spectrum conditions of the calibrated mass spectrometer; the method comprises the following steps: preparing a standard solution containing an antiviral drug, analyzing the standard solution, constructing a standard curve of the standard solution, and calculating a response coefficient of an LC-MS / MS module; and analyzing the extracted sample to obtain a sample mass spectrum and a sample chromatogram, and calculating the content of the antiviral drug. According to the method, the sensitivity and accuracy of trace analysis of the antiviral drugs in the sewage can be improved.
Owner:江苏省连云港环境监测中心 +1

Airway stent

The invention provides an airway stent, and relates to the technical field of airway stents. Ozone gas is contained in the storage bottle body, the internal space of the storage bottle body is in a circular ring shape, and a sealing bottle cap is buckled on the top of the storage bottle body; the memory metal support is located in the annular space in the storage bottle body. A rubber sealing ring is installed in the sealing bottle cap, the storage bottle body is sleeved with a movable sleeve shell, and the top of the movable sleeve shell is connected with the sealing bottle cap. A spring is connected into the movable sleeve shell and connected with the storage bottle body. When the memory metal stent is placed in the airway of a patient, the melt degradation film is degraded by body fluid, the inhibition medicine is slowly released from the slow release micropores, and granulation hyperplasia in the airway is inhibited for a long time. The problems that an existing medical airway stent mostly adopts a coating film drug-containing mode for adjuvant therapy, due to the fact that an outer side coating film is thin, the drug content is small, the drug contained in the coating film can be completely released in a short time, and the effect is not long enough are solved.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

Pramipexole oral soluble film composition as well as preparation method and application thereof

The invention provides a pramipexole oral soluble film composition as well as a preparation method and application thereof. The invention provides a pramipexole oral soluble film composition. The pramipexole oral soluble film composition comprises an active medicine, a film-forming material, a plasticizer and a flavoring agent, the active drug is a hydrochloride of S-2-amino-4, 5, 6, 7-tetrahydro-6-(propylamino)-benzothiazole as shown in a formula I and / or other pharmaceutically acceptable salt forms of the hydrochloride of S-2-amino-4, 5, 6, 7-tetrahydro-6-(propylamino)-benzothiazole as shown in the formula I. The pramipexole oral soluble film composition has the advantages that the pramipexole oral soluble film composition is thin in thickness, fast in disintegration, free of grit feeling after being dissolved in the oral cavity, capable of improving the taste of a medicine and improving the compliance of a patient, capable of being instantly dissolved in the oral cavity without drinking water, fast in oral absorption speed, uniform in film appearance, high in tensile capacity, good in flexibility and long in service life. Meanwhile, the raw materials are easy to obtain, the process is simple, the operation is simple and convenient, the drug loading capacity is high, the drug content uniformity is good, and the preparation method is suitable for industrial production. # imgabs0 #
Owner:SHANGHAI BOCIMED PHARMA CO LTD +1

Pramipexole oral soluble film composition, preparation method therefor and use thereof

PCT designated stage expiredWO2025026438A1Organic active ingredientsNervous disorderDrug contentPramipexole
A pramipexole oral soluble film composition, a preparation method therefor and the use thereof. A pramipexole oral soluble film composition containing an active drug, a film-forming material, a plasticizer and a flavoring agent, wherein the active drug is a hydrochloride and / or other pharmaceutically acceptable salt forms of S-2-amino-4,5,6,7-tetrahydro-6-(propylamino)-benzothiazole as shown in formula I. The pramipexole oral soluble film composition has the advantages of a small thickness, rapid disintegration, no gritty sensation after dissolving in the oral cavity, improved drug taste, good mouth feel, improved patient compliance, instant dissolution in the oral cavity without the need to drink water, fast absorption after taking orally, uniform film appearance, strong tensile strength, good flexibility, convenient transportation and storage, etc. In addition, the composition has the advantages of readily available raw materials, a simple process, simple and convenient operation, a high drug-loading capacity, and good uniformity of drug content, and is suitable for industrial production.
Owner:SHANGHAI BOCIMED PHARMA CO LTD +1

Melatonin implant and preparation method thereof

The invention relates to the technical field of veterinary drug preparation production, and discloses a melatonin implant, the melatonin implant comprises an embedded core and a coating, the coating is sprayed on the surface layer of the embedded core, the embedded core comprises the following components by mass: 65-75% of melatonin, 8-12% of a carrier, 10-15% of a lubricant, and 7-9% of a first plasticizer; the coating comprises the following components: a film-forming agent, a second plasticizer and a solvent, the mass ratio of the film-forming agent to the second plasticizer is (1.5-2.5): 1, and the ratio of the mass of the film-forming agent to the volume of the solvent is (2.5-3.5): 100 (g / mL). The implant has large drug loading capacity and can be slowly released for a long time, and only 13% of the implant can be released in vitro for 28 days. The melatonin implant can be prepared by adopting a hot melt extrusion and coating method, and the preparation method has the advantages of simple process, continuous production, short and stable production period, less material loss, better drug content uniformity and high technical yield, and is beneficial to expanded production.
Owner:NORTHWEST A & F UNIV +1

Anti-idiotype antibodies and uses

The invention discloses an anti-idiotypic antibody and application, the provided anti-idiotypic antibody is a monoclonal antibody capable of being specifically combined with a corresponding PD-L1 antibody drug, and the content of the antibody drug in a human body is reflected through the anti-idiotypic antibody; the anti-idiotype antibody disclosed by the invention is prepared by adopting a hybridoma technology, and an ADA kit adopting the antibody can quantitatively detect the concentration level of a PD-L1 antibody drug in vivo, and has a remarkable effect in pharmacokinetic research.
Owner:WUHAN DAIAN BIOTECH LTD

Compound SYN045 soft capsules and process for their preparation

The present application belongs to the technical field of pharmaceutical preparations, and specifically provides a compound SYN045 soft capsule and a preparation method thereof. The present application adopts a fixed proportion of plant oil and polyoxyethylene glyceryl oleate combination to prepare the content, which helps to reduce the degradation of SYN045 in the content drug solution, ensures the stability of the active ingredient, and obtains a compound SYN045 soft capsule with good drug dissolution, high drug content, low impurity generation, and high bioavailability. Further, through prescription optimization of the soft capsule shell, a fixed proportion of plasticizer is selected, the mass ratio of glycerol and sorbitol is 1:2-3, the transfer of the compound SYN045 to the soft capsule shell is reduced, and thus the quality stability problem of the soft capsule preparation product during drug storage is solved.
Owner:SHIJIAZHUANG NO 4 PHARMACEUTICAL CO LTD

Pretreatment method and application of mirabegron resin compound

The invention discloses a pretreatment method and application of a mirabegron resin compound, and relates to the pretreatment method of the mirabegron resin compound, which comprises the following steps: extracting the mirabegron resin compound by an extraction solvent to obtain a sample to be detected for detection; wherein the extraction solvent comprises an aprotic solvent, an ionized solvent and a counter-ion solvent. According to the method, a multi-factor synergistic strategy is adopted, the extraction time of mirabegron in the mirabegron resin compound is remarkably shortened, the medicine extraction efficiency is remarkably improved, the extraction method is high in recovery rate, meanwhile, comprehensive optimization of quality is ensured, a foundation is laid for accurate determination of the medicine content, the consistency of the medicine effect is ensured, and the method is suitable for large-scale popularization and application. The requirements of links such as drug research and development, production and quality control are met.
Owner:SHENZHEN BEIMEI PHARM CO LTD

Method for measuring one or more indexes of non-viral nucleic acid vector

A method for measuring drug content indexes of a non-viral nucleic acid vector composition, comprising performing labeling by enabling a permeable nucleic acid dye to be in contact with a non-viral nucleic acid vector (for example, an mRNA-LNP). The drug content indexes are calculated by measuring, at a single-particle level, fluorescent light generated by free nucleic acids of a nucleic acid vector, and fluorescent light generated by externally adsorbed nucleic acids and internally entrapped nucleic acids of the non-viral nucleic acid vector. The drug content indexes include a drug loading capacity, entrapment efficiency and the like. The method optionally further comprises: treating a sample with a nuclease before or after performing labeling by using the permeable nucleic acid dye, and when performing treatment with the nuclease, measuring the fluorescence condition of the non-viral nucleic acid vector composition; or enabling the permeable nucleic acid dye to be in contact with the sample, and then measuring the fluorescence condition of the non-viral nucleic acid vector composition.
Owner:NANOFCM INC

A kind of aluminum carbonate double-layer sheet and preparation method thereof

A magnesium aluminum carbonate double-layer tablet is obtained by pressing a magnesium aluminum carbonate common layer and a magnesium aluminum carbonate sustained-release layer, wherein the magnesium aluminum carbonate common layer contains magnesium aluminum carbonate as a main drug, and the auxiliary materials are a filler and a disintegrant, and the magnesium aluminum carbonate sustained-release layer contains magnesium aluminum carbonate as a main drug, and the auxiliary materials are a drug administration rate regulator, a gastric floating additive, a swelling agent, a foaming agent, and a hydrophilic gel. The magnesium aluminum carbonate double-layer tablet prepared by the present invention has a stable performance within 24 months, and the main drug content of the common layer and the sustained-release layer hardly changes. The common layer of the magnesium aluminum carbonate double-layer tablet can be completely peeled off from the sustained-release layer in about 30 seconds and sink into the lower layer, quickly neutralizing gastric acid and taking effect quickly. At the same time, the sustained-release layer has a release time of up to 4 hours after forming a floating layer, which proves that the magnesium aluminum carbonate double-layer tablet has a sustained-release effect within 4 hours after administration, and can effectively prolong the treatment time of patients with gastric ulcer and duodenal ulcer.
Owner:CHONGQING CONQUER PHARML

Sustained-release microsphere preparation containing texipatide or pharmaceutically acceptable salt thereof and preparation method of sustained-release microsphere preparation

The present invention relates to a pharmaceutical composition which does not undergo rapid initial burst release of a drug by comprising sustained release microspheres consisting of texipatide or a pharmaceutically acceptable salt thereof, an initial burst release inhibitor, and a biodegradable polymer, has a high drug content with respect to particle size, and has high bioavailability, thus, the composition can minimize patient pain and inflammatory response that may occur when administered to a human body, and thus can be effectively used in the prevention or treatment of diabetes, beta cell dysfunction, hypertension, hyperlipidemia, obesity, and non-alcoholic steatohepatitis.
Owner:G2GBIO INC

Feed anthelmintic blending and mixing device

ActiveCN223517359UFeeding-stuffRotary stirring mixersAnimal scienceAnthelmintic drug
The utility model relates to the technical field of anthelmintics, and discloses a feed anthelmintics blending and mixing device which comprises a mixing barrel, a feeding pipe and a discharging pipe are arranged on one side of the upper end of the mixing barrel and the middle of the lower end of the mixing barrel respectively, a barrel cover is detachably arranged at the upper end of the mixing barrel, a pesticide feeding pipe is arranged above the barrel cover, and a stirring shaft is rotatably connected to the middle of the lower portion of the barrel cover. The stirring shaft is driven by a motor fixedly arranged above the barrel cover, a spiral stirring blade is fixedly arranged on the stirring shaft, a square stirring frame is arranged on the stirring shaft and located on the outer side of the spiral stirring blade, a plurality of stirring blocks are arranged on two side plates of the square stirring frame, and a plurality of barrier strips are arranged on the inner wall of the mixing barrel. The stirring device has the advantages that the stirring effect on feed and anthelmintic is good, the uniformity is high, and the situation that the local drug content is too high is prevented.
Owner:XINJIANG AGRI UNIV

Tamsulosin hydrochloride sustained release preparation and preparation method thereof

The invention provides a tamsulosin hydrochloride sustained release preparation and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: spraying an ethanol water solution of tamsulosin hydrochloride on a mesoporous silica carrier, and drying to obtain a drug-containing carrier; mixing the drug-containing carrier, an auxiliary carrier, an adhesive and water, and carrying out wet granulation to obtain a drug-containing soft material; extruding and rounding the medicine-containing soft material to obtain a medicine-containing pellet core; coating the drug-containing pellet core with a coating solution to obtain a coated pellet core; the coating liquid comprises an enteric-coated material and a plasticizer; and mixing the coated pellet core with a lubricant to obtain the tamsulosin hydrochloride sustained release preparation. The tamsulosin hydrochloride sustained-release preparation prepared by the method is good in drug content stability, stable in main drug release, simple in process, high in controllability and suitable for industrial production.
Owner:SHANDONG INOMIC INST OF PHARM RES CO LTD

Ambroxol orally disintegrating film composition, method of preparation and use thereof

The application provides an ambroxol oral dissolving film composition, a preparation method and application thereof. The ambroxol oral dissolving film composition comprises an active drug, a film forming material and a taste masking agent, and the active drug is 2-amino-3,5-dibromo-N-(trans-4-hydroxycyclohexyl) benzylamine and / or a pharmaceutically acceptable salt thereof, for example, ambroxol hydrochloride. The ambroxol oral dissolving film composition provided by the application has the advantages of thin thickness, good taste, stable properties, immediate dissolution in the oral cavity without drinking water, and fast oral absorption speed. Moreover, the ambroxol oral dissolving film composition has the advantages of simple process, high drug loading, good drug content uniformity, and good market prospect.
Owner:SHANGHAI BOCIMED PHARMA CO LTD +1

Drug content detection method combining respiration simulation device and HPLC (High Performance Liquid Chromatography)

The invention provides a medicine content detection method combining a respiration simulation device and HPLC (High Performance Liquid Chromatography), which relates to the technical field of medicine detection and comprises the following steps: establishing a mathematical expression of a target medicine net peak area and a target medicine concentration under each respiration parameter combination and a mapping relation between the respiration parameter combination and a target medicine reference peak area; therefore, the target drug net peak area of the to-be-detected gas is determined, a plurality of similar breathing parameter combinations similar to the breathing state under the current breathing parameter combination are screened out, and the accurate value of the target drug concentration of the to-be-detected gas is determined by combining the corresponding confidence coefficient, so that the accuracy of the detection result is ensured, and the detection efficiency is improved. A mathematical expression for solving the target drug concentration under the current breathing parameter combination is established without multiple calibration tests, so that the workload is greatly reduced, and the drug concentration detection efficiency is improved.
Owner:ZHEJIANG FURUIXI PHARM CO LTD

A multi-module collaborative drug content uniformity detection pretreatment system and method

The application discloses a multi-module cooperative medicine content uniformity detection pretreatment system and method, and belongs to the technical field of medicine detection. The system comprises a container processing module, a fluid processing module, a constant volume module, a mixing module, a transfer module and a control system. The container processing module realizes automatic cap pulling and cap pressing of non-standard capacity bottles; the fluid processing module realizes liquid injection and pipetting; the constant volume module realizes automatic constant volume through visual identification; the mixing module realizes automatic liquid mixing; the transfer module automatically transfers containers between modules; the control system determines the operation sequence, controls the transfer module to sequentially transfer the containers and triggers each module to perform operations, and simultaneously receives state feedback. Through multi-module cooperative linkage, the application realizes full-process automation of plaster medicine detection pretreatment without manual intervention, significantly improves processing efficiency, precision and consistency, and has state monitoring and data tracing functions.
Owner:TOPOLOGY FUTURE TECHNOLOGY (CHANGSHA) CO LTD

sutures

The invention relates to a suture thread material comprising at least one polymer and at least one eutectic mixture. The polymer can be a biocompatible polymer such as polycaprolactone or PLGA. The eutectic mixture comprises triclosan. Other eutectic mixtures can be used in suture thread materials to reduce SSis and / or to decrease pain and / or to increase lubricity of sutures. The invention also provides a method for the production of sutures with drug loadings, the method comprising the use of therapeutic deep eutectic solvent (THEDES) technology to significantly increase drug content in suture matrices.
Owner:QUEENS UNIV OF BELFAST

Agricultural product drug residue detection device based on Raman spectrum

The utility model discloses an agricultural product drug residue detection device based on Raman spectrum, and relates to the field of detection devices. The device comprises a full-spectrum pesticide residue detector main body, a detection bin arranged on the top end face of the full-spectrum pesticide residue detector main body, a detection groove formed in the detection bin and used for supporting a detection tube, and a bin cover rotationally connected with a bin opening of the detection bin. According to the agricultural product pesticide residue detection device based on the Raman spectrum, the feeding mechanism is arranged on the top end surface of the bin cover, so that an agricultural product detection sample can be directly added into a detection tube under the condition that the detection tube containing the agricultural product detection sample is not taken out; the pesticide content in agricultural product detection samples of different quantities can be conveniently detected, the feeding mechanism can meet the stable feeding requirements of detection tubes of different sizes through the arranged positioning mechanism, and the practicability is good.
Owner:WUXI RUCHUANG TECH CO LTD

Qingkailing dropping pill and preparation method thereof

The invention provides Qingkailing dropping pills and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine extraction and preparations, the Qingkailing dropping pills comprise the following raw materials: cholic acid, nacre mother of pearl, hyodeoxycholic acid, cape jasmine, cornu bubali, isatis root, baicalin and honeysuckle; the preparation method comprises the following steps: providing pill paste powder, wherein the pill paste powder is prepared by sequentially drying mixed thick paste under reduced pressure and crushing; the mixed thick paste comprises the following raw materials: a honeysuckle extract, an isatis root-cape jasmine extract, a buffalo horn-nacre mother-of-pearl extract and a cholic acid-baicalin concentrated solution; providing a matrix, and melting and mixing the matrix with the pill paste powder to prepare a molten liquid; and providing a condensing agent, dropwise adding the molten liquid into the condensing agent, and carrying out shrinkage molding, so as to obtain the finished product dropping pill, namely the Qingkailing dropping pill. According to the preparation method, the melting and mixing efficiency and effect of the pill paste powder and the matrix are improved, the texture of molten liquid is more uniform, the content distribution of all effective components is more uniform, the medicine content uniformity in the finished dropping pill is improved, and the obtained finished dropping pill is high in stability, round in appearance and good in uniformity.
Owner:BAOTOU CHINESE TRADITIONAL MEDICINE

Automatic granulation process of boiling granulation dryer

The invention discloses an automatic granulation process of a boiling granulation dryer. The automatic granulation process comprises the following steps: S1, building a granulation system; s2, when a fluidized bed is preheated to the feeding temperature, powder is fed into the fluidized bed, and then the powder is heated to the set material temperature; s3, starting automatic segmented granulation; s4, the materials are dried for t5 minutes in a delayed mode; s5, starting material coloring; s6, drying the materials for t7 minutes; and S7, the air inlet temperature is reduced, dry cold air is conveyed into the fluidized bed, the material temperature is reduced, and when the material temperature is smaller than or equal to the discharging temperature value, shutdown is conducted, and the materials are output. According to the invention, the traceability and reducibility of batch products are ensured, and the defects of manual operation are overcome; in the granulating process, the material bed collapse is avoided, and the fullness and uniformity of the medicine component of each granule are ensured.
Owner:SICHUAN JIAMA MECHANICAL MFG CO LTD +1

GK001 solid preparation as well as preparation method and application thereof

The invention provides a GK001 solid preparation as well as a preparation method and application thereof. The solid preparation comprises the following components: a GK001 amorphous solid dispersion, an excipient, a diluent, a disintegrating agent and a lubricant, the GK001 has a structure as shown in a formula I which is described in the specification. According to the invention, GK001 is creatively prepared into a solid preparation in the form of amorphous solid dispersion, and the solid preparation has excellent stability and fluidity and high oral availability. The preparation is moderate in hardness and stable in quality, the process requirements are met, and the friability and disintegration time limit both meet the requirements; the dissolution rate of the preparation is basically consistent with the drug content, the plasma exposure is high, and the oral dose of the drug and the plasma exposure are in a linear relationship.
Owner:HONG KONG PHARMACEUTICAL CO LTD

Medication assistant graphical user interface for electronic devices

ActiveCN309093003SDrug contentPharmacist
1. The name of the product of this design: Graphical user interface for medication assistant for electronic devices. 2. Purpose of the product of this design: an electronic device. 3. The design highlights of this appearance design product are the graphical user interface on the screen. 4. The picture or photo that best illustrates the key points of the design: Main view of Design 1. 5. Designate Design 1 as the base design. 6. Purpose of the graphical user interface: It is used by doctors, pharmacists, patients, and consumers to query drug information, drug instructions, clinical guidelines, and prescriptions to guide drug use. 7. Area of ​​Graphical User Interface in the product: the interface on the screen. 8. Human-computer interaction method of graphical user interface: Design 1: After the user opens the mini program, he enters the main view of Design 1, and clicks the check box in the main view of Design 1 and then clicks one-click login to enter the interface change state diagram 1 of Design 1, which displays the family medication record and personal information. By clicking Modify, he enters the interface change state diagram 2 of Design 1, which displays the modified information and allows him to modify the information. Click View in the interface change state diagram 2 of Design 1 to enter the interface change state diagram 3, which displays the medical information. Design 2: After opening the mini program, the user enters the main view of Design 2. By entering the main view of Design 2, the interface change status diagram 1 of Design 2 displays the hospital drugs. Click on the right side of the query bar to select the drug category to enter the interface change status diagram 2, which displays the selection of specific categories of drugs. Design 3: After the user opens the mini program, he enters the main view of Design 3, and enters the interface change state diagram 1 of Design 3 through the main view of Design 3, which displays the drug instructions. Select the public product instructions and click to enter the interface change state 2 of Design 3, which displays the content information of the drug instructions and slides down to enter the interface change state diagram 3 of Design 3, which displays the connection information of the drug contents, slides down to enter the interface change state diagram 4 of Design 3, which displays the connection information of the drug contents, slides down to enter the interface change state diagram 5 of Design 3, which displays the connection information of the drug contents, slides down to enter the interface change state diagram 6 of Design 3, which displays the connection information of the drug contents, slides down to enter the interface change state diagram 7 of Design 3, which displays the connection information of the drug contents, slides down to enter the interface change state diagram 8 of Design 3, which displays the connection information of the drug contents. Design 4: After the user opens the mini program, he enters the main view of Design 4, and through the main view enters the interface change state diagram 1 of Design 4, which displays the guideline query classified by department, year, language, and favorites. Click the department to enter the interface change state diagram 2 of Design 4 to display the specific department. In the interface change state diagram 1 of Design 4, click the annual fee to enter the interface change state diagram 3 of Design 4 to display the year of the query. In the interface change state diagram 1 of Design 4, click the language to enter the interface change state diagram 4 of Design 4 to display the language of the query. In the interface change state diagram 1 of Design 4, click the favorite to enter the interface change state diagram 5 of Design 4 to display the favorite guides. In the interface change state diagram 1 of Design 4, click the guideline queried by category to enter the interface change state diagram 6 of Design 4, the requirements for the guideline query, and the reading guide.
Owner:JIANGSU WEIYAO INFORMATION TECH CO LTD

Analysis method for determining main drug content of lansoprazole sodium bicarbonate capsule

The invention belongs to the technical field of chemical analysis, and discloses an analysis method for determining the content of a main drug of a lansoprazole sodium bicarbonate capsule, and the main scheme is as follows: a methanol-water-triethylamine mixed solution is taken as a diluent, and after dissolution, an ultraviolet spectrophotometry (UV) is directly adopted for determination at the wavelength of 264 nm by an external standard method. According to experiments, methanol and water in the diluent can effectively dissolve the substance, triethylamine as alkali can effectively protect degradation of lansoprazole in the dissolving process, and compared with a determination method for the content of the product in the 2020 edition of Chinese Pharmacopoeia, the determination analysis method has the advantages of high efficiency, convenience, economy and the like.
Owner:SHANGHAI SINE WANXIANG PHARMA +1